Last updated: April 30, 2026
What is infigratinib phosphate and where is it in clinical development?
Infigratinib phosphate (BMS-?; marketed as Truseltiq in several jurisdictions for FGFR-driven disease) is an oral, selective FGFR tyrosine kinase inhibitor designed to target tumors with FGFR alterations. Its development and regulatory footprint center on previously treated advanced malignancies with FGFR pathway alterations, with the major commercial anchor in cholangiocarcinoma.
Key clinical and regulatory milestones (commercially relevant)
- Cholangiocarcinoma (FGFR2 fusions or other FGFR alterations):
- The pivotal evidence base is the Phase 2 program used for label-defining response rates and durability, leading to regulatory approvals for previously treated locally advanced or metastatic disease with FGFR2 fusions or rearrangements.
- Earlier-line and broader FGFR-alteration programs:
- Development has extended into additional cohorts and trials to expand tumor types and line of therapy, but the commercial revenue engine remains centered on the cholangiocarcinoma indication.
Source basis: the product’s dosing/indication and label framework are anchored in regulatory label disclosures and associated clinical trial publications/registries. (See citations at end.)
What is the current clinical trials update status that matters commercially?
A business-relevant trials update for infigratinib should focus on (1) label expansion, (2) sequencing competition, and (3) whether ongoing studies change estimated eligible patient pools or duration on therapy.
Commercially actionable trial read-through
- Ongoing label expansion risk/offset: Trials in earlier lines or in biomarker-defined subgroups can pull forward adoption but also intensify payer and clinician scrutiny on head-to-head positioning versus competing FGFR inhibitors and standard oncology regimens.
- Sequencing dynamics: As FGFR class competitors gain adoption, the key forecast variable is whether infigratinib maintains first-in-class status in the biomarker-defined, previously treated setting or loses share to newer agents with higher response rates, improved tolerability, or more favorable dosing schedules.
- Biomarker diagnostics and prevalence: Real-world size of eligible populations is driven by access to FGFR testing and the proportion of tumors with treatable alterations (fusion/rearrangement vs point mutations vs amplifications).
How does the competitive landscape shape uptake and price realization?
Infigratinib’s commercial trajectory depends on FGFR inhibitor competitive structure and payer frameworks for biomarker-defined oncology drugs.
FGFR competitor set (pricing and sequencing pressure)
- Other FGFR inhibitors used in FGFR-driven cholangiocarcinoma and related settings create substitution risk, especially when clinical outcomes are comparable.
- In biomarker-defined oncology, formularies tend to require:
- Confirmation of FGFR alteration via validated assays
- Evidence of prior therapy (unless label expansion occurs)
- Documentation of performance status and organ function
Key adoption constraints
- Testing bottlenecks: Delay or failure to obtain FGFR results reduces treatable patients.
- Line-of-therapy gating: If infigratinib remains restricted to later lines, addressable market remains constrained by second-line treatment penetration.
- Duration of benefit: Payers and clinicians indirectly tie value to time-on-treatment and response durability in previously treated populations.
Clinical-mechanism anchor: The drug is an FGFR inhibitor; its value proposition is class-dependent and biomarker-defined. (See citations.)
What is the market size logic for cholangiocarcinoma, and what portion is addressable?
Market modeling for infigratinib is best built on a bottom-up chain:
- Incidence of advanced cholangiocarcinoma
- Proportion with FGFR alterations eligible by label
- Proportion treated in the relevant line
- Proportion with access to testing and managed-care coverage
- Market share capture given competitive alternatives
Bottom-up addressable market structure
Below is a projection framework, using the standard approach for biomarker-oncology drugs:
Addressable TAM (before share and access)
- Advanced cholangiocarcinoma patients in the relevant geography
- FGFR2 fusion/rearrangement (and related label-defined FGFR alterations)
- Previously treated share (based on label)
SAM (after diagnostics and payer gating)
- Tested and eligible patients
- Covered by payer formularies
- Treated with FGFR-directed therapy in the line of therapy specified
SOM (infigratinib share)
- Substitution among FGFR inhibitors based on:
- Clinical outcomes and tolerability
- Route and dosing burden
- Local prescribing patterns
- Evidence depth in specific biomarker subsets
Anchor references: cholangiocarcinoma epidemiology and FGFR-driven biology are summarized in major oncology market research and clinical review materials (see citations).
What is the demand outlook under three adoption scenarios?
Given the absence of a single authoritative, continuously updated commercial dataset in this prompt, the forecast is expressed as an adoption and revenue framework rather than a point estimate that would be fabricated without a defined pricing and country coverage basis.
Scenario definitions (share and time-on-treatment assumptions)
Use the same TAM chain and vary:
- Share capture (uptake against competing FGFR inhibitors)
- Duration on treatment (drives number of prescriptions per patient)
- Label expansion success (drives line-of-therapy expansion)
Scenario A: Conservative
- Limited label expansion adoption
- Share pressured by competitors
- Testing constraints persist
Scenario B: Base
- Steady adoption in the approved line
- Moderate share against peers
- Some incremental growth from biomarker testing expansion
Scenario C: Upside
- Faster uptake through earlier lines or expanded biomarker coverage
- Strong persistence on therapy
- Broader clinician comfort and payer coverage
Revenue projection model (template)
Define:
- Addressable patients (SAM): P
- Share to infigratinib: S
- Prescriptions per year per treated patient: R (driven by duration on therapy and dosing schedule)
- Net price per prescription: N
- Annual revenue: P × S × R × N
A business can populate N from local list price and expected rebates. A model can then be stress-tested on S and R.
Why this structure holds: FGFR biomarker drugs are inherently constrained by eligibility and testing, so share and persistence dominate revenue variance.
What specific clinical endpoints and safety factors drive payer and clinician adoption?
Commercial adoption of FGFR inhibitors in cholangiocarcinoma turns on:
- Objective response rate (ORR) and duration of response (DoR)
- Progression-free survival (PFS) signals
- Tolerability and adverse event management (dose reductions, interruptions)
Safety and dosing practicality
- FGFR inhibition class risks commonly influence persistence:
- Hyperphosphatemia and ocular events are typical class considerations
- Dose modifications can affect real-world duration on therapy
This impacts R in the revenue model and affects S through clinician willingness to start and continue therapy.
What are the key value inflection points for infigratinib over the next 24 to 48 months?
The forecast should treat the next two years as a sequence of value inflection checkpoints:
- Regulatory and label actions
- Label expansion to earlier lines or broader biomarker definitions increases SAM.
- Comparative data and sequencing
- Data that improves head-to-head positioning can lift share S.
- Real-world adoption friction
- Improved testing access reduces eligibility loss between diagnosis and treatment start.
Where does uncertainty sit, and how should it be used in decision-making?
For forecasting, the high-impact uncertainty buckets are:
- FGFR-positive prevalence by assay and geography
- Line-of-therapy penetration for FGFR-directed therapy
- Competitive share under evolving evidence and payer policies
- Persistence under AE management and dose modifications
In decision terms: validate TAM with diagnostics coverage, then treat share and persistence as the primary forecast variables.
Key tables for a decision-ready projection
1) Market modeling chain (bottom-up)
| Stage |
Variable |
Role in forecast |
Main driver of variance |
| TAM |
Advanced cholangiocarcinoma incidence |
Sets baseline eligible disease |
Geography and epidemiology |
| Biomarker |
FGFR alteration prevalence |
Filters for label-defined eligibility |
Assay sensitivity and clinical interpretation |
| Line of therapy |
Previously treated penetration |
Sets how many patients reach indicated line |
Treatment patterns and guideline adoption |
| Access |
Testing and payer coverage |
Converts eligible to treated |
Formularies, prior auth, sequencing rules |
| Share |
Infigratinib vs competitors |
Converts treated to revenue |
Comparative efficacy, tolerability, evidence strength |
| Persistence |
Time on therapy |
Sets prescriptions per patient |
AE management, dose intensity, durability |
2) Adoption scenarios (directional)
| Scenario |
Share S |
Persistence R |
Net effect on revenue |
| Conservative |
Lower |
Shorter/fragmented |
Flat to modest growth |
| Base |
Moderate/steady |
Medium |
Growth in line with label baseline |
| Upside |
Higher |
Longer |
Meaningful acceleration |
Key Takeaways
- Infigratinib’s market is structurally constrained by FGFR-alteration eligibility and line-of-therapy gating in advanced cholangiocarcinoma.
- A decision-grade projection should use a bottom-up eligibility chain and then apply share (S) and persistence (R) as the dominant revenue levers.
- Near-term value inflection is driven by label expansion, sequencing evidence, and reductions in diagnostic and payer friction.
- Commercial competitiveness against other FGFR inhibitors will determine share capture and thus the slope of adoption.
FAQs
-
What is the main commercial indication for infigratinib?
Advanced cholangiocarcinoma with FGFR alterations in patients with prior therapy, per label framework.
-
What drives the addressable patient pool most?
FGFR alteration prevalence and the proportion of patients who receive and pass validated FGFR testing before treatment.
-
What determines forecast revenue most: price or volume?
Volume in this model is driven by eligibility, share, and persistence; net price affects the final conversion but not the underlying patient funnel.
-
How do safety and dose modifications affect revenue?
They change real-world persistence (duration on therapy), which directly impacts prescriptions per patient.
-
Which events would likely change the revenue trajectory fastest?
Label expansions to earlier lines and new clinical data that improves competitive positioning and payer coverage.
References
[1] U.S. Food and Drug Administration. TRUSELTIQ (infigratinib) prescribing information. FDA label.
[2] EMA. Truseltiq (infigratinib) summary of product characteristics. European label.
[3] NCI (National Cancer Institute). Cholangiocarcinoma overview (incidence and disease context).
[4] ClinicalTrials.gov. Infigratinib study listings and status updates.
[5] Peer-reviewed clinical publications on infigratinib in FGFR-altered cholangiocarcinoma (Phase 1/2 and pivotal evidence describing response and durability).
[6] Reviews and biomarker literature on FGFR alterations in cholangiocarcinoma and implications for targeted therapy.
